MENUMembers of the Rogel Cancer Center present at ASH 2024
Media contact: Anna Megdell, 734-764-2220 | Patients may contact Cancer AnswerLine™ 800-865-1125
Photo courtesy by ASH
The 66th American Society of Hematology 2024 annual meeting, will be Dec. 7-10 at the San Diego Convention Center in San Diego, California, and online.
University of Michigan faculty and trainees will present or moderate more than two dozen sessions and posters. Check out the list of U-M presenters to support your colleagues. Connect with researchers on X (Twitter) using #ASH24. Be sure to tag @UMRogelCancer.
Presenter information is sometimes incomplete. If your session is missing, please email the abstract link to [email protected].
Saturday, December 7
11:00 AM-2:00 PM. Room 29
A Violent Graft in a Vulnerable Host: The Future of aGVHD Management
Sung W. Choi, M.D., M.S., chair
Chelsea Honstain, M.S., FNP-C, speaker
Gianni Scappaticci, Pharm.D., speaker
12:15 PM. Room 29
128 Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A and B on Fitusiran Antithrombin-Based Dosing Regimen: ATLAS-OLE
Steven W. Pipe, M.D.
12:15 PM. Room 31
158 Improving Guideline Concordant Primary Prevention Aspirin Use through a Multiclinic Antithrombotic Stewardship Intervention
Jordan K Schaefer, M.D., M.Sc.
1:15 PM. Room 31
162 Cost-Effectiveness of Universal Duffy Testing at 9-12 Months: An Effort Towards Equity in Interpreting Absolute Neutrophil Counts (ANC)
Lauren E. Merz, M.D., M.Sc.
2:00 PM-3:30 PM. Room 31
113 Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Identification of New Molecular Targets to Modulate Sickle Cell Disease
Rami Khoriaty, M.D., moderator
3:00 PM. Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)
203 ETS1 Recruits the Canonical Baf Complex to Reactivate the Hematopoietic Stem Cell MYB Enhancer in the T-Cell Leukemia Context
Carea Mullin
2:00 PM-3:30 PM. Room 11
Treating Fairly - The Role of Quality Improvement in Combating Health Care Disparities
Angela C Weyand, M.D., co-chair
2:00 PM-3:30 PM. Room 11
MSHIELD: A Statewide Approach to Improving Equity Centered Quality Improvement
Melissa Creary, Ph.D., M.P.H.
2:15 PM. Room 31
170 The Saga Complex Member TADA2B Is a Novel Regulator of γ-Globin Production
Claire Drysdale, B.Sc.
3:00 PM. Pacific Ballroom Salons 15-17
233 CDK9 Is a Vulnerability in GATA-3 Driven and MCL-1 Independent T-Cell Lymphomas
Chenguang Wang, Ph.D.
Posters 5:30-7:30 PM, Halls G-H
1528 Identification of Novel Genes Underlying Human AML Expansion at Relapse from Chemotherapy
Darren King, M.D.
1245 Risk Determination in Pediatric Patients for Venous Thromboembolism
Kyle Loi
1737 Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial
Yasmin H. Karimi, M.D.
Sunday, December 8
4:30 PM - 6:30 PM. Room 25
Improving Systems-Level Management of Anticoagulants Within and Across Care Settings
Geoffrey D Barnes, M.D., M.Sc.
5:00 PM. Room 6CF
699 Treatment Versus Prophylactic Apixaban or Rivaroxaban for Extended Venous Thromboembolic Disease Management
Jordan K Schaefer, M.D., M.Sc.
Posters 6:00 PM – 8:00 PM, Halls G-H
3105 Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma
Iman Ahmed, Pharm.D.
3264 Inhibition of Endoplasmic Reticulum Associated Degradation Is Cytotoxic to Relapsed Refractory Multiple Myeloma through Altered Proapoptotic Signaling
Erin M Kropp, M.D., Ph.D.
3431 IFN1 Blockade Enhances Non-Activated CAR T Cell Anti-Tumor Function Via Inhibiting the Innate Anti-Viral Response
Joseph Durgin, M.D.
Monday, December 9
2:45 PM – 4:15 PM. Pacific Ballroom Salons 18-19
Lymphomas: Translational Molecular and Genetic: Molecular Profiling and Prognostic Biomarkers in Hodgkin and Non-Hodgkin Lymphomas
Sami N. Malek, M.D., moderator
4:00 PM. Pacific Ballroom Salons 18-19
858 Single Cell Atlas of Cutaneous T Cell Lymphomas Reveals XPO1 Dependency
Chenguang Wang, Ph.D.
4:45 PM. Room 28 A-D
938 The LSD1 Inhibitor RN1 Rescues Congenital Dyserythropoietic Anemia Type II
Lei Yu, Ph.D.
Posters 6:00 PM – 8:00 PM, Halls G-H
3911 Evaluating Treatment-Related Outcomes in the Era of Targeted Therapy for Rosai Dorman and Erdheim Chester Disease
Sabrina R Wilcox, M.D.
4477 Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study
XI Yang, M.D.
3932 12-Hepe Regulates the Antiplatelet Effects of Epa, the ω-3 Fatty Acid
Krista A Goerger, B.Sc.
3933 Comparison of the Anti-Platelet and Anti-Thrombotic Effects of the Dual SGLT1/2 Inhibitor Sotagliflozin to the Relatively Selective SGLT2 Inhibitor Empagliflozin
Livia Stanger
4131 Crispri Essentiality Screen Reveals the Essential Enhancers and Oncogenes Comprising the “Regulome” of the Notch-Collaborating Transcription Factor ETS1 in Human T-ALL
Karena Hsijan Lin
4151 AML Blasts Intrinsic Interferon Production Causes Resistance to Venetoclax in Human Acute Myeloid Leukemia Via Upregulation of MCL1, BCL2A1 and BCL-XL
Josephine Dubois
3978 Disparities in Real-World Treatment Patterns Among Patients with Von Willebrand Disease in a Large US Population-Based Dataset
Angela C Weyand, M.D.
5021 Evaluation of Heavy Menstrual Bleeding in Adolescents within the Primary Care Setting
Asavari Rajpurkar, M.D
4480 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma
Yasmin H. Karimi, M.D.
4743 MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Matthew Pianko, M.D.